GSA CAPITAL PARTNERS LLP - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 117 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 2.69 and the average weighting 0.2%.

Quarter-by-quarter ownership
GSA CAPITAL PARTNERS LLP ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$258
-62.3%
23,058
-27.9%
0.02%
-67.6%
Q2 2023$684
-56.1%
31,972
-16.9%
0.07%
-55.8%
Q1 2023$1,557
+202.9%
38,493
+248.1%
0.15%
+140.6%
Q4 2022$514
-99.8%
11,057
+76.0%
0.06%
+106.5%
Q2 2021$276,000
-43.8%
6,281
-41.4%
0.03%
-62.2%
Q3 2020$491,000
+137.2%
10,715
+159.3%
0.08%
-28.7%
Q2 2020$207,000
-77.4%
4,132
-72.1%
0.12%
+7.5%
Q4 2019$916,000
+219.2%
14,829
+210.3%
0.11%
+174.4%
Q3 2019$287,000
-72.0%
4,779
-60.7%
0.04%
-66.1%
Q2 2019$1,026,000
-30.3%
12,160
-21.0%
0.12%
-22.8%
Q1 2019$1,471,000
+67.5%
15,400
+24.2%
0.15%
+47.5%
Q4 2018$878,000
-32.4%
12,400
-18.4%
0.10%
+40.3%
Q3 2018$1,299,000
-54.1%
15,200
-37.7%
0.07%
-48.6%
Q2 2018$2,828,000
+503.0%
24,400
+320.7%
0.14%
+460.0%
Q1 2018$469,000
-15.0%
5,800
-38.3%
0.02%
-26.5%
Q4 2017$552,000
-40.1%
9,400
-52.3%
0.03%
-46.0%
Q3 2017$922,000
+216.8%
19,700
+143.2%
0.06%
+231.6%
Q2 2017$291,000
-88.8%
8,100
-89.5%
0.02%
-87.7%
Q4 2016$2,590,000
+19.1%
77,309
-5.4%
0.16%
+32.5%
Q3 2016$2,175,000
-28.1%
81,740
-40.4%
0.12%
-29.9%
Q2 2016$3,026,000
-18.7%
137,240
+8.3%
0.17%
-29.5%
Q1 2016$3,720,000
+40.3%
126,675
+57.7%
0.24%
+82.3%
Q4 2015$2,652,000
+31.9%
80,322
+44.3%
0.13%
+31.3%
Q3 2015$2,011,000
-15.5%
55,652
+5.2%
0.10%
+8.8%
Q2 2015$2,380,000
+25.9%
52,910
-14.3%
0.09%
+21.3%
Q1 2015$1,890,000
+416.4%
61,709
+757.1%
0.08%
+188.5%
Q4 2014$366,000
-60.1%
7,200
-69.0%
0.03%
-45.8%
Q3 2014$918,00023,2000.05%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q1 2015
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 511,186$43,686,00011.23%
GREAT POINT PARTNERS LLC 210,400$17,981,0002.80%
ARMISTICE CAPITAL, LLC 456,000$38,970,0002.34%
Matarin Capital Management, LLC 210,208$17,964,376,0001.16%
Sapphire Star Partners LP 8,168$698,0000.70%
Granahan Investment Management 103,320$8,830,0000.48%
FARALLON CAPITAL MANAGEMENT LLC 867,500$74,137,0000.44%
361 CAPITAL LLC 19,040$1,627,0000.35%
ALGERT GLOBAL LLC 17,922$1,532,0000.33%
AlphaMark Advisors, LLC 9,310$796,0000.32%
View complete list of ENANTA PHARMACEUTICALS INC shareholders